Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'

Journal of Clinical Investigation

Volumn 98, Issue 3, 1996, Pages 863-874

  Reverter, J C ^a   Beguin S ^b   Kessels, H ^a   Kumar, R ^b   Hemker, H C ^a,b   Coller, B S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

c7E3 Fab; glycoprotein IIb IIIa; platelets; restenosis; thrombin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BUCLADESINE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; ISOBUTYLMETHYLXANTHINE; PLATELET DERIVED GROWTH FACTOR; PROTHROMBIN; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DRUG MECHANISM; FIBRIN CLOT; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RESTENOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0029914728     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118859     Document Type: Article

References (72)

1. Walsh, P.N., and A.H Schmaier. 1994. Platelet-coagulant protein interactions. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. R.W. Colman, J. Hirsh, V.J. Marder, and H.W. Salzman, editors. J.B. Lippincott Co., Philadelphia. 629-651.
2. Wyshock, E.G., G.J. Stewart, and R.W. Colman. 1994. Thrombin-stimulated human platelets express molecular forms of α-granule factor V (FV), which differ from FVa. Thromb. Haemostasis. 72:947-956.
3. Coller, B.S., K. Anderson, and H.F. Weisman. 1995. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb. Haemostasis. 74:302-308.
4. EPIC investigators. 1994. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330: 956-961.
5. Schwartz, S.M. 1993. Serum-derived growth factor is thrombin? J. Clin. Invest. 91:94-98.
6. Topol, E.J., R.M. Califf, H.F. Weisman, S.G. Ellis, J.F., Tcheng, S. Worley, R. Ivanhoe, B.S. George, D. Fintel, M. Weston, et al. 1994. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet (N. Am. Ed.). 343: 881-886.
7. Béguin, S., T. Lindhout, and H.C. Hemker. 1989. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb. Haemostasis. 61:25-29.
8. Béguin, S., H. Kessels, F. Dol, and H.C. Hemker. 1992. The consumption of antithrombin III during coagulation, its consequences for the calculation of the prothrombinase activity and the standardization of heparin activity. Thromb. Haemostasis. 68:136-142.
9. Hemker, H.C., S. Wielders, H. Kessels, and S. Béguin. 1993. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb. Haemostasis. 70:617-624.
10. Kessels, H., S. Béguin, H. Andree, and H.C. Hemker. 1994. Measurement of thrombin generation in whole blood. The effect of heparin and aspirin. Thromb. Haemostasis. 72:78-83.
11. Coller, B.S., E.I. Peerschke, L.E. Scudder, and C.A. Sullivan. 1983. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like slate in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest. 72:325-338.
12. Coller, B.S. 1985. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Invest. 76:101-108.
13. Coller, B.S., E.I. Peerschke, L.E. Scudder, and C.A. Sullivan. 1983. Studies with a murine monoclonal antibody that abolishes ristocetin-induced hinding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood. 61:99-110.
14. Coller, B.S., J.H. Beer, L.E. Scudder, and M.H. Steinberg. 1984. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood. 74:182-192.
15. Kutok, J.L., and B.S. Coller. Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency. Thromb. Haemostasis. 72:964-972.
16. Kohmura, C., H.K. Gold, T. Yasuda, R. Holk, M.A. Nedelman, J.L. Guerrero, H.L. Weisman, and D. Collen. 1993. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler. Thromb. 13:1837-1842.
17. Cheresh, D.A., and R.C. Spiro. 1987. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J. Biol. Chem. 262:17703-17711.
18. Newman, P.G., R.W. Allen, R.A. Kahn, and T.J. Kunicki. 1985. Quantitation of membrane glycoprotein IIIa on intact human platelets using the monoclonal antibody. AP-3. Blood. 65:227-232.
19. Gretch, D.R., M. Suter, and M.F. Stinski. 1987. The use of biotinylated antibodies and steptavidin affinity chromatography to isolate herpes virus hydrophobic proteins or glycoproteins. Anal. Biochem. 163:270-277.
20. Coller, B.S., D.A., Cheresh, F., Asch, and U. Seligsohn. 1941. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood. 77:75-83.
21. Coller, B.S., K.T. Springer, L.E. Seudder, J.L. Kutok, M. Ceruso, and G.D. Prestwich 1993. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage inactivation. J. Biol. Chem. 268:20741-20743.
22. Beer, J.H., K.T. Springer, and B.S. Coller. 1992. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood. 79:117-128.
23. Hemker, H.C., G.M. Willems, and S.A. Béguin. 1986. Computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb. Haemostasis. 56:9-17.
24. 2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood. 66:1456-1459.
25. Fox, J.E.B., C.D. Austin, C.C. Reynolds, and P.K. Steffen. 1991. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J. Biol. Chem. 266:13289-13295.
26. Tsujinaka T., J. Kajiwara, J. Kambayashi, M. Sakon, N. Higuchi, T. Tanaka, and T. Mori. 1988. Synthesis of a new cell penetrating calpain inhibitor (calpeptin). Biochem. Biophys. Res. Commun. 153:1201-1208.
27. Bevers, E.M., P. Comfurius, J.L.M.L. Van Rijn, C. Hemker, and R.F.A. Zwaal. 1982. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur. J. Biochem. 122: 429-436.
28. Thiagarajan, P., and J.F. Tait. 1990. Binding of annexin V/placental anticoagulant protein I to platelets. J. Biol. Chem. 265:17420-17423.
29. Bevers, E.M. P. Comfuriusm and R.F.A. Zwaal. 1993. Mechanisms involved in platelet procoagulant response. In Mechanisms of Platelet Activation and Control. K.S. Authi, et al., editors. Plenum Publishing Corp., New York. 195-207.
30. Majerus, P.W., and J.P. Miletich. 1978. Relationship between platelets and coagulation factors in hemostasis. Annu. Rev. Med. 29:41-49.
31. Nesheim, M.E., E. Furmaniak-Kazmierczak, C. Henin, and G. Cot. 1993. On the existence of platelet receptors for factor V(a) and factor VIII(a). Thromb. Haemostasis. 70:80-86.
32. Sandberg, H., L.-O. Andersson, and S. Hoglund. 1982. Isolation and characterization of lipid-protein particles containing platelet factor 3 released from human platelets. Brochem. J. 203:303-311.
33. Sims, P.J., E.M. Faioni, T. Wiedmer, and S.J. Shattil. 1988. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J. Biol. Chem. 263:18205-18212.
34. Sims, P.J., T. Wiedmer, C.T. Esmon, H.J. Weiss, and S.J. Shattil. 1989. Assembly of the platelet prothrombinase complex is linked to vesiculation on the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J. Biol. Chem. 264:17049-17057.
35. Weiss, H.J. 1994. Scott syndrome - a disorder of platelet coagulant activity. Semin. Hematol. 31:312-319.
36. Swords, N.A., P.B. Tracy, and K.G. Mann. 1993. Intact platelet membranes, not platelet-released microparticles support the procoagulant activity of adherent platelets. Arterioscler. Thromb. 13:1613-1622.
37. Østerud, B., S.I. Rapaport, and K.K. Lavine. 1977. Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activa* tor. Blood. 49:819-834.
38. Baruch, D., H.C. Hemker, and T. Lindhoat. 1986. Kinetics of thrombin-induced release and activation of platelet factor V. Eur. J. Biochem. 154:213-218.
39. Tracy, P.B., M.E. Nesheim, and K.G. Mann. 1983. Protcolytic alterations of factor Va bound to platelets. J. Biol. Chem. 258:662-669.
40. Hultin, M.B. 1985. The modulation of thrombin activation of factor VIII by caleium ions, phospholipids and platelets. Blood. 66:53-58.
41. Neuenschwander, P., and J. Jesty. 1988. A comparison of phospholipid and platelets in the activation of human factor VIII by thrombin and factor Xa, and in the activation factor X. Blood. 72:1761-1770.
42. Rawala-Sheikh, R., S.S. Ahmad, B. Ashby, and P.N. Walsh. 1990. Kinetics of coagulation factor X activation by platelet-bound factor IXa. Biochemistry. 29:2606-2611.
43. 2, platelet factor 4, and fibrinopeptide A in bleeding-time blood of patients deficient in von Willebrand factor, platelet glycoproteins Ib and IIb-IIIa, and storage granules. Blood. 82:481-490.
44. Weiss, H.J., V.T. Turitto, and H.R. Baumgartner. 1986. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. J. Clin. Invest. 78:1072-1082.
45. Jaffe, E.A. 1994. Biochemistry, immunology, and cell biology of endothelium. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd edition. R.W. Colman, J. Hirsch, V.J. Marder, and E.W. Salzman, editors J.B. Lippincott Co., Philadelphia. 718-744.
46. Rickles, F.R., and R.L. Edwards. 1994. Leukocytes and tumor cells in thrombosis. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd edition. R.W. Colman, J. Hirsch, V.J. Marder, and H.W. Salzman, editors. J.B. Lippincott Co., Philadelphia. 1164-1179.
47. Bevers, E.M., P. Comfurius, and R.F. Zwaal. 1991. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev. 5:145-154.
48. Weitz, J.I., M. Hudoba, D. Massel, J. Maraganore, and J. Hirsch. 1990. Clot- bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86:385-391.
49. Reed, G.L. G.R. Matsueda, and E. Haber. 1992. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin. Thromb. Haemostasis. 68:315-320.
50. Zoldhelyi, P., V. Fuster, and J.H. Chesebro. 1992. Antithrombins as conjunctive therapy in arterial thrombolysis. Coron. Artery. Dis. 3:1003-1009.
51. Anderson, H.V. 1993. Restenosis after coronary angioplasty. Disease A Month. 39:613-670.
52. Kyrle, P.A., J. Westwick, M.F. Scully, V.V. Kakkar, and G.P. Lewis. 1987. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man - effect of low-dose aspirin. Thromb. Haemostasis. 57:62-66.
53. Hampton, K.K., C. Cerletti, L.A. Loizou, F. Bucchi, M.B. Donati, J.A. Davies, G. de Gaetano, and C.R.M. Prentice. 1990. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo. Thromb. Haemostasis. 64:17-20.
54. Szczeklik, A., M. Krzanowski, P. Gora, and J. Radwan. 1992. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 80:2006-2011.
55. Basic-Micic, M., C. Roman, U. Herpel, E. Kling, B. Scholz, and H.K. Breddin. 1992. Platelet-induced thrombin generation time: a new sensitive global assay for platelet function and coagulation. Haemostasis. 22:309-321.
56. Moorehead, M.T., J.C. Westengard, and B.S. Bull. 1984. Platelet involvement in the activated coagulation time of heparinized blood. Anesth. Analg. 63:394-398.
57. Yasu, T., S. Oshima, M. Imanishi, H. Nonogi, K. Haze, M. Juramochi, T. Omae, Y. Havashi, and S. Yamamoto. 1993. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. Am. J. Cardiol. 71:1164-1168.
58. Andreotti, F., G.J. Davies, S.P. Ujang, and P. Sritara. 1993. High-dose aspirin, thrombin, and coronary angioplasty. Lancet (N. Am. Ed.) 341:1161.
59. Coller, B.S. 1992. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as a conjunctive therapy for coronary artery disease, Coron. Artery. Dis. 3: 1016-1029.
60. Cook, N.S., G. Kottirsch, and H.-G. Zerwes. 1994. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future. 19:135-159.
61. Cadroy, Y., S.R. Hanson, B.K. Andrew, U.M. Marzec, B.L. Evatt, T.J. Kunicki, R.R. Montgomery, and L.A. Harker. 1994. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood. 83:3218-3224.
62. Moliterno, D.J. R.M. Califf, F.V. Aguirre, K. Anderson, K.M. Sigmon, H.F. Weisman, and E.J. Topol. 1995. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting lime during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the prevention of ischemic complications trial. Am. J. Cardiol. 75: 559-562.
63. Bevers, E.M., P. Comfurius, and H.K. Nieuwenhuis. 1986. Platelet prothrombin converting activity in hereditary disorders of platelet function. Br. J. Haematol. 63:335-346.
64. Hardisty, R.M., K.M. Dormandy, and R.A. Hutton. 1964. Thrombasthenia: studies on three cases. Br. J. Haematol. 10:371-387.
65. Caen, J.P., P.A. Castaldi, and J.C. Leclerc. 1966. Congenital bleeding disorders with long bleeding time and normal platelet count. I. Glanzmann's thrombasthenia. Am. J. Med. 41:4-26.
66. Zucker, M.B., J.H. Pert, and M.W. Hilgartner. 1966. Platelet function in a patient with thrombasthenia. Blood. 28:524-534.
67. Weiss, H.J., and S. Kochwa. 1968. Studies of platelet function and proteins in 3 patients with Glanzmann thrombasthenia. J. Lab. Clin. Med. 7:153-165.
68. Cohen, I., D.L. Burk, and J.G. White. 1989. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb-IIIa complex on the development of clot tension. Blood. 73:1880-1887.
69. Carr, M.E., Jr., S.L. Carr, R.R. Hantgan, and J. Braaten. 1995. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces elastic modulus. Thromb Haemostasis. 73:499-505.
70. Hoffman, M., D.M. Monroe, and H.R. Roberts. 1993. Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometry study. Thromb. Haemostasis. 68:74-78.
71. Gemmell, C.H., M.V. Sefton, and E.L. Yeo. 1993. Platelet derived microparticle formation involves glycoprotein IIb/IIIa. Inhibition by RGDS and Glanzmann's thrombasthenia defect. J. Biol. Chem. 268:14586-14589.
72. Nomura, S., Y. Komiyama, T. Murakami, A. Funatsu, T. Kokawa, T. Sugo, M. Matsuda, and K. Yasunaga. 1993. Flow cytometric analysis of surface membrane proteins on activated platelets and platelet-derived microparticles from healthy and thrombasthenic individuals. Intl. J. Hematol. 58:203-212.